On Tuesday, Baird initiated coverage on Alto Neuroscience (NYSE:ANRO), a company operating in the major depressive disorder (MDD) space, with an Outperform rating and a price target of $32.00. The firm highlighted Alto Neuroscience's innovative approach to developing treatments for neuropsychiatric conditions, particularly MDD.
Alto Neuroscience is recognized for its strategy of designing drugs tailored to biomarker-identified subpopulations within the MDD space. The approach is designed to increase the likelihood of a successful response to therapy.
Baird's analyst noted the potential for substantial upside in the company's shares, especially with the key Phase 2b results expected for ALTO-100 and ALTO-300.
These results are anticipated in the second half of 2024 and the first half of 2025, respectively. The analyst expressed optimism about the drugs' market potential, suggesting that robust efficacy results could position each drug to capture a significant share of the MDD market, potentially supporting multi-billion dollar peak sales opportunities.
Alto Neuroscience's progress in the MDD market is closely watched by investors, with the upcoming clinical trial readouts serving as critical milestones for the company. The positive outlook from Baird reflects confidence in the company's targeted approach to drug development and its potential impact on the treatment of MDD.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.